Analysis criticizes relaxed FDA conflict-of-interest rules

06/10/2013 | MedPage Today (free registration)

Allowing more experts with industry ties to serve on FDA advisory panels could allow more products with dangerous side effects to make it to market, an analysis published in the journal Science says. A 2007 law capped the number of waivers the agency could grant for experts with industry ties, but a 2012 law lifted the cap. Waivers were granted for fewer than 1% of the 608 experts who participated in advisory committees through the first half of 2013, and the agency posts online notice of waivers in advance of meetings, says FDA spokeswoman Stephanie Yao.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ